Alterola Biotech, Inc.
ABTI
Other OTC0.00
USD
- -
- -
CIK
0001442999
ISIN
US02152V1035
CUSIP
02152V103
Return %
Stock
S&P500
1Y
0.00
18.86
3Y
-97.94
64.57
5Y
-99.99
71.65
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- David John Hitchcock
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 47 Hamilton Square Birkenhead MR United Kingdom CH41 5AR
- IPO Date
- May 5, 2010
- CIK
- 0001442999
- Website
- alterola-abti.com
- Similar Companies
- Business
- Alterola Biotech, Inc. operates as a pharmaceutical company specializing in the discovery, development, and commercialization of novel therapeutics derived from cannabinoid, cannabinoid-like, and non-cannabinoid molecules. The company offers a broad product pipeline including proprietary cannabinoid molecules, cannabinoid pro-drugs, nano-encapsulated cannabinoid formulations in self-dissolving polymers, and topical ocular cannabinoid formulations. Its product segments include regulated pharmaceuticals for human and animal health; low-cost pharmaceutical-grade active pharmaceutical ingredients (APIs) and food-grade ingredients sourced from synthetic, biosynthetic, and botanical methods; and drug delivery technologies that enhance therapeutic efficacy and bioavailability. Alterola serves markets primarily in the UK, Europe (Ireland, Netherlands), USA, Australia, and China. Founded in 2008, it is headquartered at 47 Hamilton Square, Birkenhead, Merseyside, United Kingdom. In recent years, Alterola has undergone significant strategic developments including the May 2021 acquisition of ABTI Pharma Limited, augmenting its cannabinoid and pharmaceutical ingredient portfolios. In 2021, it also acquired assets from C2 Wellness Corporation expanding its intellectual property and technology platforms in cannabinoid-based medicines. In 2022, Alterola established a strategic partnership with Bright Green Corporation, securing a $4 million investment and an option for further acquisition, aimed at enhancing manufacturing and distribution capabilities of federally compliant pharmaceutical-grade cannabis products. The company upgraded its OTC market listing to OTCQB to increase visibility and investor engagement. Leadership changes in 2022 included the appointment of David Hitchcock as CEO and Terry Rafih joining the board, reflecting a focus on scaling clinical development and research capabilities. Alterola focuses on advancing cannabinoid therapeutics through multiple development methodologies including botanical extraction, traditional chemical synthesis, and biosynthetic approaches. Its active development pipeline targets a variety of clinical indications with proprietary intellectual property rights on multiple drug candidates and formulations designed for targeted delivery systems such as lymphatic and ocular routes. The company has positioned itself as a vertically integrated pharmaceutical entity involved in drug ingredient production, product formulation, and regulated pharmaceutical development across global markets. Its operations leverage acquisitions and partnerships to expand technological capabilities and market reach within the cannabinoid pharmaceutical sector.